Letters to the Editor

Stroke welcomes Letters to the Editor and will publish them, if suitable, as space permits. They should not exceed 750 words (including references) and may be subject to editing or abridgment. Please submit letters in duplicate, typed double-spaced. Include a fax number for the corresponding author and a completed copyright transfer agreement form (available online at http://stroke.ahajournals.org and http://submit-stroke.ahajournals.org).

Cathepsin Enzymes and Cystatin C: Do They Play a Role in Positive Arterial Remodeling?

To the Editor:

We have read the impressive article recently published by Aoki et al evaluating the cathepsin enzyme system in cerebral aneurysm formation. By using quantitative RT-PCR and immunohistochemistry, the authors have demonstrated increased expression of cathepsin B, cathepsin K, and cathepsin S in arterial wall of the cerebral aneurysms, whereas the expression of cystatin C was found to be decreased. These findings suggest an imbalance between cysteine cathepsins and their inhibitor. This imbalance may cause the excessive breakdown of extracellular matrix in the arterial wall resulting in progressing arterial aneurysm formation. This conclusion was supported by the experimental use of the cathepsin inhibitor NC-2300.

Cystatin C is a ubiquitously expressed, secretory protein that inactivates members of the cathepsin family of cysteine proteases, and subsequently plays a role in protein catabolism, antigen presentation, bone resorption, hormone processing, and which couples to cleavage of membrane and extracellular matrix proteins during tissue remodeling.2–4 The role of cystatin C in cardiovascular diseases has gained an interest in recent years. Although some studies have reported decreased expression of cystatin C in atherosclerotic lesions and increased atherosclerosis in the absence of cystatin C,5–7 there is growing evidence that the reduction or inhibition in cystatin C expression correlates with dilating vascular disease. These vascular dilatations, namely coronary artery ectasia, abdominal aortic aneurysm or cerebral artery aneurysm can be regarded as positive arterial remodeling which are associated with the enlargement of the external elastic laminae of the corresponding vessel walls.

Recently, decreased cystatin C levels have been shown in patients with coronary artery ectasia coexisting with obstructive coronary artery disease, when compared to patients with coronary artery disease alone.8 Moreover, patients with abdominal aortic aneurysm were shown to have higher levels of cathepsin enzyme activity and lower levels of cystatin C as compared to patients with obstructive abdominal aortic disease. These data suggest that cystatin C positively correlates with obstructive atherosclerotic disease.9 It has already been demonstrated that dilated vascular segments are often not localized to a single vascular territory. Increased, several dilating vascular diseases such as abdominal aortic aneurysm,10 coronary artery ectasia,11,12 cerebral artery aneurysm12,13 and venous system dilation14,15 may coexist, suggesting that a systemic abnormality may explain these vascular wall destructions.16 It is therefore reasonable to assume that the observed changes in cathepsin and cystatin C expression and activity may be the common denominator that may be found in patients with multiple manifestations of dilating vascular diseases.

Regarding the inhibitory effects of cystatin C on catabolic cathepsin enzymes, it is reasonable to expect increased vascular wall destruction leading to dilatation in involved segments. Beyond the possible inverse association between the atherosclerosis and cystatin C, it is becoming more and more obvious that decreased cystatin C expression level is associated with dilating vascular disease or positive arterial remodeling. As firstly proven by animal study of Aoki et al,1 cathepsin enzymes and cystatin C may be good targets for novel therapeutic interventions aiming in decelerating or preventing the progression of aneurysmal disease.

Disclosures

None.

Ertan Yetkin, MD
Department of Cardiology
University Hospital Maastricht, and Cardiovasc Res Institute Maastricht (CARIM)
University of Maastricht
Maastricht, The Netherlands

Johannes Waltenberger, MD, PhD
Department of Cardiology
University Hospital Maastricht, and Cardiovasc Res Institute Maastricht (CARIM)
University of Maastricht
Maastricht, The Netherlands

Cathepsin Enzymes and Cystatin C: Do They Play a Role in Positive Arterial Remodeling?
Ertan Yetkin and Johannes Waltenberger

*Stroke*. 2009;40:e26-e27; originally published online December 18, 2008;
doi: 10.1161/STROKEAHA.108.537423

*Stroke* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://stroke.ahajournals.org/content/40/2/e26

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Stroke* is online at:
http://stroke.ahajournals.org/subscriptions/